Nikola V. NEDELJKOVIĆ, Miloš V. NIKOLIĆ, Ana S. STANKOVIĆ, Nevena S. JEREMIĆ, Dušan Lj. TOMOVIĆ, Andriana M. BUKONJIĆ, Gordana P. RADIĆ, Marina Ž. MIJAJLOVIĆ

Virtual screening, drug-likeness analysis, and molecular docking study of potential severe acute respiratory syndrome coronavirus 2 main protease inhibitors

Due to the length of time required to develop specific antiviral agents, the World Health Organization adopted the strategy of repurposing existing medications to treat Coronavirus disease 2019 infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease is possible biological target for potential antiviral drugs. We selected various compounds from PubChem database based on the structure of main protease inhibitors in Protein Data Bank database. Ten compounds showed nontumorigenic and nonmutagenic potential and met Egan’s and Lipinski’s rules. Molecular docking analysis was performed using AutoDock Vina software. Based on number and type of key binding interactions, as well as docking scores, we selected compounds 6, 8, and 17 that demonstrated the highest binding affinity for the target protein. Molecular dynamics simulations were then carried out on the protein-top docked ligand complexes which were subjected to molecular mechanics/generalized Born and surface area calculations. The molecular dynamics simulation results indicated that protein-top docked ligand complexes showed good conformational stability. Among analyzed molecules, compound 17 emerged as the best in silico hit based on the docking score, MM/GBSA binding energy and MD results.

PDF

___

1. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmacological Reviews 2014; 66 (1): 334-395. doi: 10.1124/pr.112.007336
2. Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules 2015; 20 (7): 13384-13421. doi: 10.3390/molecules200713384
3. Narkhede RR, Cheke RS, Ambhore JP, Shinde SD. The molecular docking study of potential drug candidates showing anti-COVID-19 activity by exploring of therapeutic targets of SARS-CoV-2. Screening 2020; 4 (3): 185-195. doi: 10.14744/ejmo.2020.31503
4. Fu L, Ye F, Feng Y, Yu F, Wang Q et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nature Communications 2020; 11 (1): 1-8. doi: 10.1038/s41467-020-18233-x
5. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian Journal of Pediatrics 2020; 87 (4): 281-286. doi: https://doi. org/10.1007/s12098-020-03263-6
6. Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019)-recent trends. European Review for Medical and Pharmacological Sciences 2020; 24 (4): 2006-2011. doi: 10.26355/eurrev_202002_20378
7. Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S et al. Drug targets for corona virus: A systematic review. Indian Journal of Pharmacology 2020; 52: 56-65. doi: 10.4103/ijp.IJP_115_20
8. Linder HA, Fotouhi-Ardakani N, Lytvyn V, Lanchance P, Sulea T et al. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. Journal of Virology 2005; 79: 15199-15208. doi: 10.1128/JVI.79.24.15199-15208.2005
9. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of antiSARS drugs. Science 2003; 300: 1763-1767. doi: 10.1126/science.1085658
10. Zhang S, Krumberger M, Morris MA, Parrocha CMT, Griffin JH et al. Structure-Based Drug Design of an Inhibitor of the SARSCoV-2 (COVID-19) Main Protease Using Free Software: A Tutorial for Students and Scientists. ChemRxiv [Preprint]. doi: 10.26434/ chemrxiv.12791954
11. Webber SE, Okano K, Little TL, Reich SH, Xin Y et al. Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. Journal of Medicinal Chemistry 1998; 41: 2786-2805. doi: 10.1021/jm980071x
12. Huang L, Ellman JA. General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain. Bioorganic & Medicinal Chemistry Letters 2002; 12 (20): 2993-2996. doi: 10.1016/s0960-894x(02)00619-4
13. Yamashita DS, Smith WW, Zhao B, Janson CA, Tomaszek TA et al. Structure and Design of Potent and Selective Cathepsin K Inhibitors. Journal of the American Chemical Society 1997; 119: 11351-11352. doi: 10.1021/ja972204u
14. Jílková A, Řezáčová P, Lepšík M, Horn M, Váchová J et al. Structural Basis for Inhibition of Cathepsin B Drug Target from the Human Blood Fluke, Schistosoma mansoni. Journal of Biological Chemistry 2011; 286 (41): 35770–35781. doi: 10.1074/jbc.M111.271304
15. Chen SH, Lamar J, Victor F, Snyder N, Johnson R et al. Synthesis and evaluation of tripeptidyl alpha-ketoamides as human rhinovirus 3C protease inhibitors. Bioorganic & Medicinal Chemistry Letters 2003; 13: 3531-3536. doi: 10.1016/s0960-894x(03)00753-4
16. Otto H-H, Schirmeister T. Cysteine Proteases and Their Inhibitors. Chemical Reviews 1997; 97: 133-172. doi: 10.1021/cr950025u
17. Al-Shar’i NA. Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations. Journal of Biomolecular Structure and Dynamics 2020; 31: 1-16. doi: 10.1080/07391102.2020.1800514
18. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS et al. Remdesivir for the Treatment of Covid-19 - Final Report. The New England Journal of Medicine 2020; 383 (19): 1813-1826. doi: 10.1056/NEJMoa2007764
19. Rochwerg B, Agarwal A, Zeng L, Leo YS, Appiah JA et al. Remdesivir for severe covid-19: a clinical practice guideline. British Medical Journal 2020; 370: 2924. doi: 10.1136/bmj.m2924
20. Cai Q, Yang M, Liu D, Chen J, Shu D et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing) 2020; 6: 1192-1198. doi: 10.1016/j.eng.2020.03.007
21. Khalili JS, Zhu H, Mak NS, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. Journal of Medical Virology 2020; 92 740-746. doi: 10.1002/jmv.25798.
22. Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020; 395: 1695-1704. doi: 10.1016/S0140-6736(20)31042-4
23. Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaei M et al. A global treatments for coronaviruses including COVID-19. Journal of Cellular Physiology 2020; 235: 9133. doi: 10.1002/jcp.29785.
24. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC et al. Hydroxychloroquine with or without Azithromycin in Mild-toModerate Covid-19. The New England Journal of Medicine 2020; 383: 2041. doi: 10.1056/NEJMoa2019014
25. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes and Metabolic Syndrome 2020; 14 (3): 241-246. doi: 10.1016/j.dsx.2020.03.011
26. Xu X, Han M, Li T, Sun W, Wang D et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences of the United States of America 2020; 117 (20): 10970–10975. doi: 10.1073/pnas.2005615117
27. Zeng YM, Xu XL, He XQ, Tang SQ, Li Y et al. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol. Chinese Medical Journal 2020; 133 (9): 1132-1134. doi: 10.1097/CM9.0000000000000790
28. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M et al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. Antimicrobial Agents and Chemotherapy 2020; 64 (9): 1061. doi: 10.1128/AAC.01061- 20
29. Zhang W, Zhao Y, Zhang F, Wang Q, Li T et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical Immunology 2020; 214: 108393. doi: 10.1016/j. clim.2020.108393
30. Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. Journal of American Medical Association 2020; 324: 1130. doi: 10.1001/ jama.2020.17023
31. Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. The American Journal of Chinese Medicine 2020; 48 (3): 737-762. doi: 10.1142/S0192415X20500378
32. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A et al. Drug treatments for covid-19: living systematic review and network meta-analysis. British Medical Journal 2020; 370: 2980. doi: 10.1136/bmj.m2980
33. Lin S, Shen R, He J, Li X, Guo X. Molecular modeling evaluation of the binding effect of ritonavir, lopinavir and darunavir to severe acute respiratory syndrome coronavirus 2 proteases. bioRxiv 2020. doi: 10.1101/2020.01.31.929695
34. Wu C, Liu Y, Yang Y, Zhang P, Zhong W et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B 2020; 10 (5): 766-788. doi: 10.1016/j.apsb.2020.02.008
35. Gul S, Ozcan O, Asar S, Okyar A, Barıs I, Kavakli IH. In silico identification of widely used and well-tolerated drugs as potential SARSCoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials. Journal of Biomolecular Structure and Dynamics 2020; 1-20. doi: 10.1080/07391102.2020.1802346
36. Egieyeh S, Egieyeh E, Malan S, Christofells A, Fielding B. Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2). PloS one. 2021; 16 (1): e0245258. doi: 10.1371/journal.pone.0245258
37. Thurakkal L, Singh S, Roy R, Kar P, Sadhukhan S et al. An in-silico study on selected organosulfur compounds as potential drugs for SARS-CoV-2 infection via binding multiple drug targets. Chemical physics letters 2021; 763: 138193. doi: 10.1016/j.cplett.2020.138193
38. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020; 586 (7830): 589-593. doi: 10.1038/s41586-020-2639-4
39. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020; 396 (10255): 887-897. doi: 10.1016/S0140-6736(20)31866-3
40. Kim S, Chen J, Cheng T, Gindulyte A, He J et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Research 2019; 47 (1): 1388-1395. doi: 10.1093/nar/gkaa971
41. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports 2017; 7 (1): 1-3. doi: 10.1038/srep42717
42. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 2001; 46 (1-3): 3-26. doi: 10.1016/s0169-409x(00)00129-0
43. Egan WJ, Merz KM Jr, Baldwin JJ. Prediction of drug absorption using multivariate statistics. Journal of Medicinal Chemistry 2000; 43 (21): 3867-3877. doi: 10.1021/jm000292e
44. Sander T, Freyss J, von Korff M, Rufener C. DataWarrior: an open-source program for chemistry aware data visualization and analysis. Journal of Chemical Information and Modeling 2015; 55 (2): 460-473. doi: 10.1021/ci500588j
45. Buntrock ER. ChemOffice Ultra7.0. Journal of Chemical Information and Modeling 2002; 42 (6): 1505-1506.
46. Macrae CF, Edgington PR, McCabe P, Pidcock E, Shields GP et al. Mercury: visualization and analysis of crystal structures. Journal of Applied Crystallography 2006; 39 (3): 453-457. doi: 10.1107/S002188980600731X
47. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry 2009; 30 (16): 2785-2791. doi: 10.1002/jcc.21256
48. Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA et al. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. Journal of Medicinal Chemistry 2020; 63 (21): 12725-12747. doi: 10.1021/acs.jmedchem.0c01063
49. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 2010; 31 (2): 455-461. doi: 10.1002/jcc.21334
50. Sadati SM, Gheibi N, Ranjbar S, Hashemzadeh MS. Docking study of flavonoid derivatives as potent inhibitors of influenza H1N1 virus neuraminidase. Biomedical Reports 2019; 10 (1): 33-38. doi: 10.3892/br.2018.1173
51. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics 1983; 79 (2): 926-935. doi: 10.1063/1.445869
52. Harder E, Damm W, Maple J, Wu C, Reboul M et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. Journal of chemical theory and computation 2016; 12 (1): 281-296. doi: 10.1021/acs.jctc.5b00864
53. Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert opinion on drug discovery 2015; 10 (5): 449-461. doi. 10.1517/17460441.2015.1032936
54. Masand VH, Rastija V. PyDescriptor: A new PyMOL plugin for calculating thousands of easily understandable molecular descriptors. Chemometrics and Intelligent Laboratory Systems 2017; 169: 12-18. doi: 10.1016/j.chemolab.2017.08.003
55. Reiner Ž, Hatamipour M, Banach M, Pirro M, Al-Rasadi K et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Archives of Medical Science 2020; 16 (3): 490. doi: 10.5114/aoms.2020.94655
56. Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. Preprints 2020. doi: 10.20944/preprints202003.0226.v1
57. Samant LR, Javle VRK. Comparative Docking analysis of rational drugs against COVID-19 Main Protease. ChemRxiv. Preprint. doi: 10.26434/chemrxiv.12136002.v1
58. Yu R, Chen L, Lan R, Shen R, Li P. Computational screening of antagonist against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. International Journal of Antimicrobial Agents 2020: 56 (2): 106012. doi: 10.1016/j.ijantimicag.2020.106012
59. Mothay D, Ramesh KV. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock. Virus Disease 2020; 31 (2): 194-199. doi: 10.1007/s13337-020-00585-z
60. Choudhary MI, Shaikh M, tul-Wahab A, ur-Rahman A. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation. PLoS One 2020; 15 (7): e0235030. doi: 10.1371/journal.pone.0235030
61. Marinho EM, de Andrade Neto JB, Silva J, da Silva CR, Cavalcanti BC et al. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease. Microbial Pathogenesis 2020; 148: 104365. doi: 10.1016/j.micpath.2020.104365
62. Pham MQ, Vu KB, Pham TN, Tran LH, Tung NT et al. Rapid prediction of possible inhibitors for SARS-CoV-2 main protease using docking and FPL simulations. RSC Advances 2020; 10 (53): 31991-31996. doi: 10.1039/D0RA06212J
63. Keretsu S, Bhujbal SP, Cho SJ. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation. Scientific Reports 2020; 10 (1): 1-4. doi: 10.1038/s41598-020-74468-0
64. Torjesen I. Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds. BMJ: British Medical Journal 2020; 369: 2263. doi: 10.1136/bmj.m2263
65. Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database of Systematic Reviews 2020 (4). doi: 10.1002/14651858.CD013587
66. Alnajjar R, Mostafa A, Kandeil A, Al-Karmalawy AA. Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease. Heliyon 2020; 6 (12): e05641. doi: 10.1016/j.heliyon.2020.e05641